ニトロプルーシドと重度の閉塞性心不全患者の地域血管容量
C Risöe1, S Simonsen, K Rootwelt
1Medical Department B, Rikshospitalet, Oslo, Norway.
Circulation
|March 1, 1992
まとめ
ナトリウムニトロプロシドは,腸および肺の容量容量器を活性的にリラックスさせ,重度の閉塞性心不全患者の静脈圧を下げる. 肝血管の体積は,圧力が低下したため,受動的に減少した可能性があります.
科学分野:
- 心血管生理学 心血管の生理学
- 薬理学 薬理学とは
- メディカルイマージング (医学イメージング)
背景:
- 肺高血圧の重症性閉塞性心不全 (CHF) 患者 (NYHAクラスIV) のナトリウムニトロプルシド効果を研究しています.
- 地域血管容量に対する影響を評価する.
研究 の 目的:
- 重度のCHFおよび肺高血圧の患者におけるナトリウムニトロプルシドの地域血管容量に対する影響を決定する.
- ナトリウムニトロプロシドによって誘発される血管容量の変化のメカニズムを解明する.
主な方法:
- 均衡血池シンチグラフィは,地域血量 (プランクニック,肺) を測定するために使用されます.
- 肝臓の静脈圧と肺動脈の圧力を測定し,膨張圧力を評価する.
- ナトリウムニトロプロシドの投与量は,シストリック肺動脈の圧力が50mmHg以下になるまで増加しました.
主要な成果:
- ナトリウムニトロプロシドは,大動脈,肺毛細血管,肝静脈の平均圧力を有意に低下させた.
- 腸内血量が大幅に増加した (26%),肝臓血量減少した (9%). 肺の血液量は変化しませんでした.
- 圧力-体積分析は,腸と肺の容量容量器の活発なリラックスを示した.
結論:
- ナトリウムニトロプルシドは,腸および肺の容量容量の血管の活発なリラックスを通じて,CHF患者の静脈圧を効果的に低下させます.
- 肝血管の体積減少は,静脈圧の低下の被動的な結果である可能性が高い.
さらに関連する動画
関連する概念動画
Antihypertensive Drugs: Vasodilators
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
Heart Failure Drugs: Inotropic Agents
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Cardiomyopathy II: Dilated Cardiomyopathy
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...


